Published in N Engl J Med on January 24, 2008
Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings. Circulation (2011) 3.16
Pathology of second-generation everolimus-eluting stents versus first-generation sirolimus- and paclitaxel-eluting stents in humans. Circulation (2013) 1.50
Impact of drug-eluting stents among insulin-treated diabetic patients: a report from the National Heart, Lung, and Blood Institute Dynamic Registry. JACC Cardiovasc Interv (2008) 1.49
Molecular genetics of myocardial infarction. Genomic Med (2008) 0.91
Benefit of long-term dual anti-platelet therapy in patients treated with drug-eluting stents: from the NHLBI dynamic registry. Am J Cardiol (2012) 0.90
Pathologic Etiologies of Late and Very Late Stent Thrombosis following First-Generation Drug-Eluting Stent Placement. Thrombosis (2012) 0.89
Long-term outcome after sirolimus-eluting stents versus bare metal stents in patients with diabetes mellitus: a patient-level meta-analysis of randomized trials. Clin Res Cardiol (2011) 0.89
Differential effects of post-dilation after stent deployment in patients presenting with and without acute myocardial infarction. Am Heart J (2010) 0.84
Comparison between on-label versus off-label use of drug-eluting coronary stents in clinical practice: results from the German DES.DE-Registry. Clin Res Cardiol (2011) 0.83
Comparison of long-term safety and efficacy outcomes after drug-eluting and bare-metal stent use across racial groups: Insights from NHLBI Dynamic Registry. Int J Cardiol (2015) 0.81
Update on the everolimus-eluting coronary stent system: results and implications from the SPIRIT clinical trial program. Vasc Health Risk Manag (2009) 0.81
Comparison of the efficacy of drug-eluting stents versus bare-metal stents for the treatment of left main coronary artery disease. Chin Med J (Engl) (2015) 0.80
Efficacy and safety of drug-eluting stents in the real world: 8-year follow-up. Arq Bras Cardiol (2014) 0.80
Bare-metal versus drug-eluting coronary stents. N Engl J Med (2008) 0.80
On-label and off-label use of drug-eluting stents: comparison of short- and long-term outcomes. Tex Heart Inst J (2012) 0.78
Risk factors for coronary drug-eluting stent thrombosis: influence of procedural, patient, lesion, and stent related factors and dual antiplatelet therapy. ISRN Cardiol (2013) 0.78
Percutaneous coronary intervention for unprotected left main coronary artery stenosis. World J Cardiol (2010) 0.78
Serial changes of neointimal tissue after everolimus-eluting stent implantation in porcine coronary artery: an optical coherence tomography analysis. Biomed Res Int (2014) 0.76
The comparative efficacy of percutaneous and surgical coronary revascularization in 2009: a review. Tex Heart Inst J (2009) 0.76
Comparison of 12-month outcomes with zotarolimus- and Paclitaxel-eluting stents: a meta-analysis. ISRN Cardiol (2011) 0.75
Safety and efficacy of overlapping homogenous drug-eluting stents in patients with acute myocardial infarction: results from Korea Acute Myocardial Infarction Registry. J Korean Med Sci (2012) 0.75
Another view of personalized medicine: optimizing stent selection on the basis of predicted benefit in percutaneous coronary intervention. Trends Cardiovasc Med (2012) 0.75
Safety and efficacy of the Yukon Choice Flex sirolimus-eluting coronary stent in an all-comers population cohort. Indian Heart J (2014) 0.75
Bare-metal versus drug-eluting coronary stents. N Engl J Med (2008) 0.75
Safety and effectiveness of drug-eluting stents in Chinese patients with coronary artery disease with off- and on-label indications: results from a single-centre registry. Heart Asia (2013) 0.75
Transradial versus transfemoral approach in patients undergoing primary percutaneous coronary intervention for ST-elevation acute myocardial infarction: insight from the CREDO-Kyoto AMI registry. Heart Vessels (2017) 0.75
Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med (2003) 13.29
A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med (2002) 12.84
A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med (2004) 11.86
Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med (2007) 5.77
Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med (2007) 5.37
Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med (2007) 4.95
Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet (2003) 4.68
Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation (2003) 3.22
The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol (2004) 2.78
TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation (2003) 2.74
Percutaneous coronary intervention in the current era compared with 1985-1986: the National Heart, Lung, and Blood Institute Registries. Circulation (2000) 2.65
Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA (2007) 2.49
Outcomes and complications associated with off-label and untested use of drug-eluting stents. JAMA (2007) 2.43
Stent thrombosis redux--the FDA perspective. N Engl J Med (2007) 1.60
Two-year outcomes after sirolimus-eluting stent implantation: results from the Sirolimus-Eluting Stent in de Novo Native Coronary Lesions (SIRIUS) trial. J Am Coll Cardiol (2006) 1.18
Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet (2006) 19.03
Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med (2011) 13.55
Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med (2003) 13.29
A variant in CDKAL1 influences insulin response and risk of type 2 diabetes. Nat Genet (2007) 13.28
Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet (2007) 12.65
A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med (2009) 12.15
Universal definition of myocardial infarction. Circulation (2007) 11.69
Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA (2011) 6.39
Refining the impact of TCF7L2 gene variants on type 2 diabetes and adaptive evolution. Nat Genet (2007) 5.88
Efficacy of a device to narrow the coronary sinus in refractory angina. N Engl J Med (2015) 5.36
Gli2, but not Gli1, is required for initial Shh signaling and ectopic activation of the Shh pathway. Development (2002) 4.80
Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) Randomized Trial. Am J Obstet Gynecol (2002) 4.18
Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology (2008) 3.89
A quantitative, randomized study evaluating three methods of mesenchymal stem cell delivery following myocardial infarction. Eur Heart J (2006) 3.43
Insights from the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study: Part II: gender differences in presentation, diagnosis, and outcome with regard to gender-based pathophysiology of atherosclerosis and macrovascular and microvascular coronary disease. J Am Coll Cardiol (2006) 3.25
Relationship of physical fitness vs body mass index with coronary artery disease and cardiovascular events in women. JAMA (2004) 3.17
Low prevalence of "ideal cardiovascular health" in a community-based population: the heart strategies concentrating on risk evaluation (Heart SCORE) study. Circulation (2011) 2.99
Non-high-density lipoprotein cholesterol levels predict five-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI). Circulation (2002) 2.95
Stent thrombosis. J Am Coll Cardiol (2010) 2.86
Liberal versus restrictive transfusion thresholds for patients with symptomatic coronary artery disease. Am Heart J (2013) 2.79
Vertebral compression fractures: pain reduction and improvement in functional mobility after percutaneous polymethylmethacrylate vertebroplasty retrospective report of 245 cases. Radiology (2003) 2.76
Persistent chest pain predicts cardiovascular events in women without obstructive coronary artery disease: results from the NIH-NHLBI-sponsored Women's Ischaemia Syndrome Evaluation (WISE) study. Eur Heart J (2006) 2.67
Clinical importance of obesity versus the metabolic syndrome in cardiovascular risk in women: a report from the Women's Ischemia Syndrome Evaluation (WISE) study. Circulation (2004) 2.67
Differential diffusivity of Nodal and Lefty underlies a reaction-diffusion patterning system. Science (2012) 2.57
Insights from the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study: Part I: gender differences in traditional and novel risk factors, symptom evaluation, and gender-optimized diagnostic strategies. J Am Coll Cardiol (2006) 2.57
Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women: the National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE). Circulation (2004) 2.50
Depression, inflammation, and incident cardiovascular disease in women with suspected coronary ischemia: the National Heart, Lung, and Blood Institute-sponsored WISE study. J Am Coll Cardiol (2007) 2.49
Adverse cardiovascular outcomes in women with nonobstructive coronary artery disease: a report from the Women's Ischemia Syndrome Evaluation Study and the St James Women Take Heart Project. Arch Intern Med (2009) 2.48
2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. J Am Coll Cardiol (2008) 2.46
Outcomes and complications associated with off-label and untested use of drug-eluting stents. JAMA (2007) 2.43
Association between extracellular matrix expansion quantified by cardiovascular magnetic resonance and short-term mortality. Circulation (2012) 2.41
Natural history of infant reflux esophagitis: symptoms and morphometric histology during one year without pharmacotherapy. Am J Gastroenterol (2006) 2.40
Influence of health care providers on the development of diabetes complications: long-term follow-up from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care (2002) 2.35
Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure. J Am Coll Cardiol (2008) 2.29
Access site hematoma requiring blood transfusion predicts mortality in patients undergoing percutaneous coronary intervention: data from the National Heart, Lung, and Blood Institute Dynamic Registry. Catheter Cardiovasc Interv (2007) 2.28
Hypotheses, design, and methods for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. Am J Cardiol (2006) 2.25
Percutaneous left atrial appendage occlusion for patients in atrial fibrillation suboptimal for warfarin therapy: 5-year results of the PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) Study. JACC Cardiovasc Interv (2009) 2.24
Factors associated with poorer prognosis for patients undergoing primary percutaneous coronary intervention during off-hours: biology or systems failure? JACC Cardiovasc Interv (2008) 2.22
Myocardial extracellular volume fraction quantified by cardiovascular magnetic resonance is increased in diabetes and associated with mortality and incident heart failure admission. Eur Heart J (2013) 2.21
Retracted Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health--National Heart, Lung, and Blood Institute sponsored Women's Ischemia Syndrome Evaluation. J Clin Endocrinol Metab (2008) 2.21
Percutaneous left atrial appendage transcatheter occlusion (PLAATO system) to prevent stroke in high-risk patients with non-rheumatic atrial fibrillation: results from the international multi-center feasibility trials. J Am Coll Cardiol (2005) 2.19
Lack of association between the Trp719Arg polymorphism in kinesin-like protein-6 and coronary artery disease in 19 case-control studies. J Am Coll Cardiol (2010) 2.17
Rosiglitazone and outcomes for patients with diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Circulation (2013) 2.15
Risk of early or severe pre-eclampsia related to pre-existing conditions. Int J Epidemiol (2007) 2.14
Clinical and demographic predictors of outcomes in recent onset dilated cardiomyopathy: results of the IMAC (Intervention in Myocarditis and Acute Cardiomyopathy)-2 study. J Am Coll Cardiol (2011) 2.10
Timing of hormone therapy, type of menopause, and coronary disease in women: data from the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation. Menopause (2011) 2.06
The economic burden of angina in women with suspected ischemic heart disease: results from the National Institutes of Health--National Heart, Lung, and Blood Institute--sponsored Women's Ischemia Syndrome Evaluation. Circulation (2006) 2.03
Clinical progression of incidental, asymptomatic lesions discovered during culprit vessel coronary intervention. Circulation (2004) 2.00
A cluster analysis of bacterial vaginosis-associated microflora and pelvic inflammatory disease. Am J Epidemiol (2005) 1.94
Hypercholesterolemia suppresses inwardly rectifying K+ channels in aortic endothelium in vitro and in vivo. Circ Res (2006) 1.85
Twenty-year evolution of percutaneous coronary intervention and its impact on clinical outcomes: a report from the National Heart, Lung, and Blood Institute-sponsored, multicenter 1985-1986 PTCA and 1997-2006 Dynamic Registries. Circ Cardiovasc Interv (2008) 1.84
Bacterial vaginosis (BV) and the risk of incident gonococcal or chlamydial genital infection in a predominantly black population. Sex Transm Dis (2005) 1.82
Randomized controlled trial of mindfulness-based stress reduction (MBSR) for survivors of breast cancer. Psychooncology (2009) 1.80
Unrestricted use of drug-eluting stents compared with bare-metal stents in routine clinical practice: findings from the National Heart, Lung, and Blood Institute Dynamic Registry. J Am Coll Cardiol (2007) 1.77
Pbx1 inactivation disrupts pancreas development and in Ipf1-deficient mice promotes diabetes mellitus. Nat Genet (2002) 1.75
Validation of Mayo Clinic risk adjustment model for in-hospital complications after percutaneous coronary interventions, using the National Heart, Lung, and Blood Institute dynamic registry. J Am Coll Cardiol (2003) 1.74
Effects of the P-selectin antagonist inclacumab on myocardial damage after percutaneous coronary intervention for non-ST-segment elevation myocardial infarction: results of the SELECT-ACS trial. J Am Coll Cardiol (2013) 1.70
Timing of in-hospital coronary artery bypass graft surgery for non-ST-segment elevation myocardial infarction patients results from the National Cardiovascular Data Registry ACTION Registry-GWTG (Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With The Guidelines). JACC Cardiovasc Interv (2010) 1.67
Endovascular management of isolated iliac artery aneurysms. J Vasc Surg (2006) 1.67
Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: a meta-analysis. Diabetes Care (2011) 1.65
Screening children to identify families at increased risk for cardiovascular disease. Pediatrics (2006) 1.62
Native coronary disease progression exceeds failed revascularization as cause of angina after five years in the Bypass Angioplasty Revascularization Investigation (BARI). J Am Coll Cardiol (2004) 1.62
Cause-specific mortality trends in a large population-based cohort with long-standing childhood-onset type 1 diabetes. Diabetes (2010) 1.60
Determination of menopausal status in women: the NHLBI-sponsored Women's Ischemia Syndrome Evaluation (WISE) Study. J Womens Health (Larchmt) (2004) 1.57
Immediate vs. delayed stenting in acute myocardial infarction: a systematic review and meta-analysis. EuroIntervention (2013) 1.55
The truth and consequences of the COURAGE trial. J Am Coll Cardiol (2007) 1.55
Sleep symptoms predict the development of the metabolic syndrome. Sleep (2010) 1.55